Target Population Size and Launch Price Dynamics of Cell and Gene Therapies: Evidence from European HTA Systems

This study explores how target population size influencesthe launch pricing and reimbursement outcomes of cell and gene therapies (CGTs)across major European HTA markets, including Germany (G-BA), France (HAS), andEngland (NICE). Using HTA-derived population estimates and publicly availablelaunch prices from 2015–2025, the study evaluates whether rarity-based pricingprinciples are reflected in real-world HTA systems.

Key findings also showed that reimbursement decisions werenot solely driven by therapy price or estimated budget impact, but alsoreflected broader considerations such as unmet need, clinical uncertainty, andcountry-specific HTA frameworks.

Please click here to download the poster.